Trial Profile

Effects of Coenzyme Q10 in Parkinson Disease - Phase III

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ubidecarenone (Primary) ; Vitamin E
Indications Parkinson's disease
Focus Therapeutic Use
Acronyms QE3

Most Recent Events

31 Jan 2013 Biomarkers information updated
21 Jun 2012 Results presented at the 16th International Congress of Parkinson's Disease and Movement Disorders.
25 Aug 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com